立方体使用和高血糖症:立方体会导致糖尿病吗?
Cindy L Bredefeld1,2, Paula Choi3, Tiffany Cullen3
1Department of Medicine, New York University Grossman Long Island School of Medicine, NYU Langone Hospital-Long Island, Garden City, NY, 11530, USA. Cindy.bredefeld@nyulangone.org.
Current atherosclerosis reports
|December 19, 2024
概括
用于预防心血管疾病的他类药物与新发糖尿病有关. 高强度他类药物和患者肥胖增加了这种风险,需要仔细考虑好处与风险.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉样性心血管疾病 (ASCVD) 和糖尿病是全球主要的健康问题.
- 类药物对于ASCVD预防至关重要,但与高血糖和新发糖尿病 (NODM) 有关.
研究的目的:
- 审查关于他类药物和糖尿病之间的关系的当前和新兴知识.
- 探索他类药物诱导的高血糖和NODM的机制和危险因素.
主要方法:
- 现有和新兴研究的文献综述.
- 对使用他类药物,高血糖和NODM发病率的数据进行分析.
主要成果:
- 在他类药物使用和发病糖尿病之间存在明显的关联.
- 高强度他类药物和患者的肥胖是NODM的主要风险因素.
- 机制的假设包括改变的胰岛素信号传递,葡萄糖运输和肠道微生物群.
结论:
- 根据个人风险因素和他类药物的特性,可以预测使用他类药物的NODM风险.
- 这种风险必须与他类药物的ASCVD风险降低益处进行权衡.
- 改善NODM风险评估沟通对于患者管理至关重要.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
531
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
531
Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
Oral Hypoglycemic Agents: Sulfonylureas
186
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
186
Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
Pathophysiology of Diabetes
862
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
862


